



1600 TYSONS BOULEVARD MCLEAN, VA 22102 703.905.2000 F: 703.905.2500

Writer's Direct Dial Number (703) 905-2173 Writer's Email: msanzo@pillsburywinthrop.com

November 26, 2001

Assistant Commissioner for Patents **BOX: Patent Application** Washington, DC 20231

> Re: New U.S. Patent Application (Division of U.S. No. 09/159,518)
> Appl. No. to be assigned Filed: herewith
> Title: Novel Opioid Peptides for the Treatment of Pain Inventor(s): Brown, et al. Atty. Dkt.: 81813/282437

Sir:

×

1.

*

The following documents are being forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

A the strugg and

A copy of application no. 09/159,518, as filed in the U.S. Patent and Trademark Office on September 24, 1998, entitled:

NOVEL OPIOID PEPTIDES FOR THE TREATMENT OF PAIN

and naming as inventor(s): William Brown John DiMaio Peter Schiller René Martel

the application comprising:

26 pages of Specification (numbered as pages 1-26); 26 pages of Claims (numbered as pages 27-52); a one-page Abstract (numbered as page 53); and 8 sheets of formal drawings (labeled as Fig. 1A-Fig. 8-B);



Assistant Commissioner for Patents November 26, 2001 Page 2

- A copy of the Declaration by Joint Inventors (37 C.F.R. § 1.63) and on Behalf of Inventor Who Refuses to Sign or Cannot Be Reached (37 C.F.R. § 1.47(a)), Power of Attorney and Petition Under 37 C.F.R. § 1.47(a), executed by inventors William Brown, Peter Schiller and Wuyi Wang, filed in the parent application (8 pages);
- 3. A copy of the Declaration by Joint Inventors (37 C.F.R. § 1.63) and on Behalf of Inventor Who Refuses to Sign or Cannot Be Reached (37 C.F.R. § 1.47(a)), Power of Attorney and Petition Under 37 C.F.R. § 1.47(a), executed by Francis Martel and Pierre Martel, co-executors of the estate of deceased inventor René Martel, filed in the parent application (8 pages);
- 4. A copy of the Declaration by Joint Inventors (37 C.F.R. § 1.63) and on Behalf of Inventor Who Refuses to Sign or Cannot Be Reached (37 C.F.R. § 1.47(a)), Power of Attorney and Petition Under 37 C.F.R. § 1.47(a), executed by Diane Martel, co-executor of the estate of deceased inventor René Martel, filed in the parent application (8 pages);
- 5. A copy of the Decision According Status Under 37 C.F.R. § 1.47(a) in the parent application (2 pages);
- 6. Statement re Deletion of Inventor (1 page);
- and the second second with the second s
- 7. Preliminary Amendment (2 pages);
- 8. Information Disclosure Statement (2 pages);
- 9. List of References Cited by Applicant (4 pages);
- 10. A copy of the recorded Assignment to Astra AB executed by inventors William Brown, John DiMaio, Peter Schiller and René Martel, filed in the grandparent application (08/292,918) (5 pages);
- 11. A copy of the recorded Assignment to changing the name of the Assignee from Astra AB to AstraZeneca AB, filed in the parent application (10 pages);

á



Assistant Commissioner for Patents November 26, 2001 Page 3

- 12. Our check in the amount of \$2,754.00 representing the following fees:
 - \$ 740.00 Basic Filing Fee (37 C.F.R. § 1.16(a)),
 - 420.00 5 independent claim in excess of 3 (37 C.F.R. § 1.16(b)),
 - 1,314.00 73 claims in excess of 20 (37 C.F.R. § 1.16(c)),
 - 280.00 Multiple dependent claim fee (37 C.F.R. § 1.16(d)), and
- 13. Two (2) return postcards.

This application is a division of U.S. application no. 09/159,518, filed September 24, 1998, which is a continuation-in-part of U.S. application 08/392,918, filed on March 3, 1995 and of 08/718,585, filed on October 2, 1996. It claims the benefit of international application PCT/SE95/00158 (filed on February 15, 1995 and published in English on August 24, 1995) and of PCT/SE96/01011 (filed on August 14, 1996 and published in English on February 27, 1997). In addition, the application claims priority to two applications filed in the United Kingdom (9403263.8, filed on February 21, 1994; and 9408179.1, filed on April 25, 1994) and three applications filed in Sweden (9401519-5, filed on May 3, 1994; 9502877-5, filed on August 18, 1995; and 9503924-4, filed on November 7, 1995)

In accordance with the requirements of 37 C.F.R. § 1.53(b), the present divisional application is being filed under the conditions specified in 35 U.S.C. § 120. The inventors named on this divisional application are as stated in Item 1 above (see Statement re Deletion of Inventor, Item 6 above) and the application is being filed before the patenting, or abandonment of, or termination of proceedings of the parent application (09/159,518).

1

An Level mail Marce

We are submitting an Information Disclosure Statement which cites references originally submitted in connection with U.S. 09/159,518. The present application relies upon 09/159,518 for priority under 35 U.S.C. § 120. Thus, in accordance with 37 C.F.R. § 1.98(d), copies of the listed references are not being resubmitted. If, for any reason, the Examiner cannot locate a listed reference, Applicants will be happy to submit a copy as a courtesy.



Assistant Commissioner for Patents November 26, 2001 Page 4

It is respectfully requested that the attached postpaid postcards be stamped with the serial number of the above-named application and that these postcards be returned as soon as possible.

Very truly yours,

PILLSBURY WINTHROP LLP

Michinel A. Sange

Michael A. Sanzo Attorney for Applicants Reg. No. 36,912

MAS:ct Enclosures

₩.

a state of the set of

30241229V1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Brown, et al.

(Division of Appl. No. 09/159,518)

Appl. No.: to be assigned

Filed: herewith

For: Novel Opioid Peptides for the Treatment of Pain Art Unit: 1631

e 1 🗄

Examiner: to be assigned

Attorney Docket: 81823/282437

Statement re Deletion of Inventor

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with 37 C.F.R. § 1.63(d)(2), Applicants' undersigned attorney hereby states that Wuyi Wang, an inventor named on parent application 09/159,518, has been deleted in the present divisional application. The deletion is due to the cancellation of claims 59-77 by Preliminary Amendment.

The Commissioner is hereby authorized to charge any fee for the filing of the present

document to our Deposit Account No. 03-3975 under order number 81823/282437.

If a phone call would help to expedite this matter, the Examiner is invited to call Applicants' undersigned attorney at (703) 905-2173.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: Michael A. Same

Michael A. Sanzo Reg. No. 36,912 Attorneys for Applicants

Date: Normher 26, 2001

1600 Tysons Boulevard McLean, VA 22102 (703) 905-2000